Close

UPDATE: Goldman Sachs Starts Editas Medicine (EDIT) at Sell, Cautious on Lead Drugs

April 16, 2021 3:08 AM EDT Send to a Friend
(Updated - April 16, 2021 4:14 AM EDT)

Goldman Sachs analyst Madhu Kumar initiates coverage on Editas Medicine (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login